口腔癌VEGF-C表达和血管及淋巴管生成与淋巴道转移关系的研究  

Vascular endothelial growth factor C,lymphangiogenesis,angiogenesis and lymphatic metastasis of oral cancer

作　　者：于大海[1] 温玉明[1] 李龙江[1] 王昌美[1] 王晓毅[1] 付风华[1] 

机构地区：[1]华西医科大学口腔医学院颌面外科

出　　处：《临床口腔医学杂志》2001年第1期6-9,共4页Journal of Clinical Stomatology

基　　金：国家自然科学基金资助! (39970 796)

摘　　要：目的　比较口腔正常及鳞癌组织血管、淋巴管密度与血管内皮生长因子 C (VEGF C)表达及淋巴道转移关系。方法　VEGF C免疫组化染色、血管、淋巴管酶组化染色、光镜及图像分析观察血管、淋巴管总体面数密度 (TNa)。结果　VEGF C表达阳性的淋巴管TNa明显高于阴性 (P <0 .0 1) ;血管TNa略高于阴性 (P >0 .0 5 )。鳞癌比正常组织、淋巴结转移组比无淋巴结转移组血管、淋巴管TNa均有增加 (P <0 .0 1)。随临床T分期增加 ,淋巴管TNa增加 (P <0 .0 1) ,而血管TNa与之无关 (P >0 .0 5 )。随病理分级增加 ,血管TNa(P <0 .0 1)、淋巴管TNa(P <0 .0 5 )均有增加。结论　VEGF C主要介导了癌周淋巴管生成 ,对血管生成有一定的影响 ;血管、淋巴管密度的同时增加可能与VEGF、VEGFObjective To compare the relationship among vascular endothelial growth factor C(VEGF C) expression,density of lymphatics,blood vessel and lymphatic metastasis in oral squamous carcinoma. Methods VEGF C protein expression was determined by immunohistochemistry.Lymphatic and blood vessel differential stain was determined by enzymehistochemical technique.Automated image analysis quantification was applied to determine the number of total lymphatic and blood vessels in unit area(TNa). Results The peri tumor lymphatic TNa of oral carcinoma was significantly higher in VEGF C positive group than those in VEGF C negative group( P < 0.01 ),but the blood TNa was a few higher( P > 0.05 ).Lymphatic TNa( P < 0.01 ) and blood TNa( P < 0.01 ) were significantly higher in oral carcinoma and in lymph node metastasis group than those in normal tissue and in no metastasis group, respectively.Blood TNa correlated with pathological grades( P < 0.05 ),but not with clinical grades( P > 0.05 ).TNa correlated with pathological grades( P < 0.05 ) and clinical grades( P < 0.01 ). Conclusion VEGF C mainly promotes peri tumor lymphangiogenesis and has a little effect to angiogenesis. Simultaneous increase of lymphatic and blood vessels may be related to the synergic expression of VEGF,VEGF C and their receptors.

关 键 词：血管内皮生因子-C 血管 淋巴管 口腔癌 淋巴道转移 

分 类 号：R739.8[医药卫生—肿瘤] R73-37[医药卫生—临床医学]